• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Politan Capital Management Lp claimed ownership of 4,611,752 shares (SEC Form 3)

    11/4/24 8:49:57 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Politan Capital Management LP

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/01/2024
    3. Issuer Name and Ticker or Trading Symbol
    Azenta, Inc. [ AZTA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Director by deputization
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.01 per share 4,611,752 I See footnotes(1)(2)(3)(4)(5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Politan Capital Management LP

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Director by deputization
    1. Name and Address of Reporting Person*
    Politan Capital Management GP LLC

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Director by deputization
    1. Name and Address of Reporting Person*
    Politan Capital Partners GP LLC

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Director by deputization
    1. Name and Address of Reporting Person*
    Koffey Quentin

    (Last) (First) (Middle)
    106 WEST 56TH STREET
    10TH FLOOR

    (Street)
    NEW YORK NY 10019

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. In addition to Politan Capital Management LP, a Delaware limited partnership ("Politan"), this Form 3 is being filed jointly by Politan Capital Management GP LLC, a Delaware limited liability company ("Politan Management"), Politan Capital Partners GP LLC, a Delaware limited liability company ("Politan GP"), and Quentin Koffey, a citizen of the United States of America (together with Politan, Politan Management and Politan GP, the "Reporting Persons"), each of whom has the same business address as Politan and may be deemed to have a pecuniary interest in securities reported on this Form 3 (the "Subject Securities").
    2. Politan is the investment advisor to certain funds, including Politan Capital Partners LP, a Delaware limited partnership ("Politan LP"), Politan Capital Offshore Partners LP, a Cayman Islands exempted limited partnership ("Politan Offshore"), and Politan Capital Partners Master Fund LP, a Cayman Islands exempted limited partnership ("Politan Master Fund") (collectively with Politan Offshore and Politan LP, the "Politan Funds").
    3. Politan, as the investment advisor of the Politan Funds, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. As the general partner of Politan, Politan Management may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. As the general partner of the Politan Funds, Politan GP may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934.
    4. By virtue of Mr. Koffey's position as managing partner and chief investment officer of Politan, and as the managing member of Politan Management and Politan GP, Mr. Koffey may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
    5. Mr. Koffey is a member of the board of directors of the Issuer of the Subject Securities, and as a result, each of the other Reporting Persons may be directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934.
    Politan Capital Management LP By: Politan Capital Management GP LLC, its General Partner /s/ Quentin Koffey, Managing Member 11/04/2024
    Politan Capital Management GP LLC /s/ Quentin Koffey, Managing Member 11/04/2024
    Politan Capital Partners GP LLC /s/ Quentin Koffey, Managing Member 11/04/2024
    /s/ Quentin Koffey 11/04/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AZTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    1/5/2026$50.00In-line → Outperform
    Evercore ISI
    12/19/2025$42.00 → $44.00Buy
    Needham
    10/30/2025$38.00Hold → Buy
    Jefferies
    8/6/2025$35.00Mkt Perform → Outperform
    Raymond James
    7/22/2025$35.00Equal-Weight
    Stephens
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

    BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado

    4/7/26 8:15:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference

    BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta p

    2/24/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    SEC Filings

    View All

    Azenta Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Azenta, Inc. (0000933974) (Filer)

    4/7/26 8:30:19 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Inc. filed SEC Form 8-K: Other Events

    8-K - Azenta, Inc. (0000933974) (Filer)

    4/2/26 4:10:36 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Azenta Inc.

    SCHEDULE 13G/A - Azenta, Inc. (0000933974) (Subject)

    3/26/26 4:10:59 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Cornog William L bought $189,884 worth of Common (7,000 units at $27.13), increasing direct ownership by 37% to 25,795 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/25/25 4:28:43 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: Director Malus Alan J bought $319,800 worth of Common (12,000 units at $26.65), increasing direct ownership by 238% to 17,035 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:07 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: President and CEO Marotta John bought $25,990 worth of Common (1,000 units at $25.99), increasing direct ownership by 0.94% to 107,296 units (SEC Form 4)

    4/A - Azenta, Inc. (0000933974) (Issuer)

    11/14/25 4:10:08 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Director Cornog William L

    4/A - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:21:57 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Director Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 6:12:14 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Director Cornog William L

    4 - Azenta, Inc. (0000933974) (Issuer)

    2/6/26 5:47:58 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Azenta upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Azenta from In-line to Outperform and set a new price target of $50.00

    1/5/26 8:28:55 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Needham reiterated coverage on Azenta with a new price target

    Needham reiterated coverage of Azenta with a rating of Buy and set a new price target of $44.00 from $42.00 previously

    12/19/25 7:47:35 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta upgraded by Jefferies with a new price target

    Jefferies upgraded Azenta from Hold to Buy and set a new price target of $38.00

    10/30/25 7:56:09 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    View All

    Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

    BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado

    4/7/26 8:15:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

    NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

    11/19/24 5:56:00 PM ET
    $AZTA
    $CON
    $ENV
    Industrial Machinery/Components
    Technology
    Medical Specialities
    Health Care

    Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

    William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

    11/4/24 8:00:00 AM ET
    $AZTA
    $BV
    $LVWR
    Industrial Machinery/Components
    Technology
    Real Estate
    Motor Vehicles

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azenta Inc.

    SC 13G/A - Azenta, Inc. (0000933974) (Subject)

    11/13/24 4:05:02 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13D/A filed by Azenta Inc.

    SC 13D/A - Azenta, Inc. (0000933974) (Subject)

    11/4/24 8:41:47 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Azenta Inc.

    SC 13G - Azenta, Inc. (0000933974) (Subject)

    10/31/24 11:55:02 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    $AZTA
    Financials

    Live finance-specific insights

    View All

    Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities

    BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l

    3/4/26 9:11:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025

    BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ

    2/4/26 6:30:00 AM ET
    $AZTA
    Industrial Machinery/Components
    Technology

    Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast

    BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide

    1/21/26 4:05:00 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology